HUBUC Launches P1, a global card issuing and processing engine, becoming a Mastercard Network Enablement Partner
15.2.2023 10:07:00 EET | Business Wire | Press release
Leading fintech company HUBUC announces the immediate availability of its revolutionary issuing processor, a Mastercard-certified platform that makes card issuing easier than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230213005527/en/
HUBUC Founders, Ignacio Javierre and Hasan Nawaz (Photo: Business Wire)
The platform has global scalability and plug-and-play connectivity at its core, allowing financial institutions and fintechs to enhance their customer experiences and deploy disruptive payment card use cases in a matter of weeks.
HUBUC decided to build P1, a new issuing processor in-house when existing ones proved to be running on legacy technology from the 1960's and provided outdated functionalities.
HUBUC's commitment with P1 is to bring lightning-fast performance, lean implementation and microservices architecture that allows scalability and innovation for years to come.
The cloud-based platform has key capabilities such as card-level spending controls, regulatory issuer reporting, cloud processing for scalability and comes with a stellar developer experience with Public Sandbox and OpenAPI specification.
Additionally, the platform offers strong customer authentication for enhanced security against fraud, and is GDPR, PSD2 and PCI DSS 3.2 Level 1 compliant.
The platform’s powerful issuing processor is the ultimate infrastructure to innovate with a Mastercard product and generate new revenue streams, improve unit economics and become a leading company in any sector.
P1 customers like Coverflex are an example of how to leverage HUBUC services. Coverflex’s solution allows a company to design more bespoke employee compensation, such as health insurance, meal allowance, fringe benefits and discounts, by aggregating multiple providers. This year Coverflex recently raised €15 million Series A, to keep increasing their existing customer base of 3,600+ companies, including Santander, Natixis, OysterHR, Bolt, Emma, Revolut and Smartex.
In a statement, Coverflex CEO Miguel Amaro said: “At Coverflex, we are dedicated to providing cutting-edge employee benefits via a smart card to our clients in Europe. Our focus on increasing the unit economics and scalability of our card product has been a top priority, and we are thrilled to announce that our partnership with HUBUC has enabled us to achieve this goal. Working with industry leaders like Ignacio and Hasan has been a truly enlightening experience, allowing us to expand our knowledge and understanding of the payments world. This collaboration has allowed us to significantly enhance our proposition to our clients, delivering increased efficiency and a better user experience for our cardholders.”
HUBUC's leadership team has been innovating in the fintech industry for years and brings experience building financial infrastructure across Europe to scale it globally.
HUBUC is backed by some of the best venture capitalists and operators in the industry, such as Y Combinator, Jeffrey Katzenberg (Managing Partner at WndrCo, Former Chairman Walt Disney Studios and DreamWorks Animations), Runa Capital, Village Global, Eric Yuan (Zoom), John Lilly (Mozilla), Immad Akhund (Mercury), John Bautista (Orrick), Charles Delingpole (ComplyAdvantage) among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005527/en/
Contact information
HUBUC Inc.
press@hubuc.com | Ignacio Javierre
https://www.hubuc.com/about-us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 10:00:00 EET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 05:36:00 EET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom